Abstract
Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95%confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 615-621 |
| Number of pages | 7 |
| Journal | International Journal of Gynecological Cancer |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - May 2013 |
Fingerprint
Keywords
- Cervical cancer
- Radiosensitivity
- Ribonucleotide reductase
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Oncology
Cite this
Ribonucleotide reductase expression in cervical cancer : A Radiation Therapy Oncology Group translational science analysis. / Kunos, Charles A.; Winter, Kathryn; Dicker, Adam P.; Small, William; Abdul-Karim, Fadi W.; Dawson, Dawn; Jhingran, Anuja; Valicenti, Richard K; Weidhaas, Joanne B.; Gaffney, David K.
In: International Journal of Gynecological Cancer, Vol. 23, No. 4, 05.2013, p. 615-621.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ribonucleotide reductase expression in cervical cancer
T2 - A Radiation Therapy Oncology Group translational science analysis
AU - Kunos, Charles A.
AU - Winter, Kathryn
AU - Dicker, Adam P.
AU - Small, William
AU - Abdul-Karim, Fadi W.
AU - Dawson, Dawn
AU - Jhingran, Anuja
AU - Valicenti, Richard K
AU - Weidhaas, Joanne B.
AU - Gaffney, David K.
PY - 2013/5
Y1 - 2013/5
N2 - Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95%confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.
AB - Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95%confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.
KW - Cervical cancer
KW - Radiosensitivity
KW - Ribonucleotide reductase
UR - http://www.scopus.com/inward/record.url?scp=84879912271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879912271&partnerID=8YFLogxK
U2 - 10.1097/IGC.0b013e31828b4eb5
DO - 10.1097/IGC.0b013e31828b4eb5
M3 - Article
VL - 23
SP - 615
EP - 621
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 4
ER -